BSG Series CM, LLC
Transaction: 04/24/2026
OTHER
Change
0
Price
Not reported
Filing
05/04/2026
Type
OTHER
Coeptis Therapeutics Holdings, Inc.
COEP • Biotechnology
$10.99
▼ -1.03 (-8.57%)
Current price
EarningsLatest report: Mar 31, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$66.29M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Positive revenue growth · 44.7%Manageable debt level · 0.02Healthy liquidity · 4.16Weak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 14, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:36 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$10.99
Change-8.57%
Shares Out6.03M
Market Cap$66.29M
Enterprise Value$61.13M
52W Range6.80 - 21.41
Beta-0.43
P/E-5.58
P/S46.89
P/B3.86
P/FCF-8.29
EV/Sales43.24
Price$10.99
Change-8.57%
Shares Out6.03M
Market Cap$66.29M
Enterprise Value$61.13M
52W Range6.80 - 21.41
Beta-0.43
P/E-5.58
P/S46.89
P/B3.86
P/FCF-8.29
EV/Sales43.24
EV/EBITDA-5.62
EV/FCF-7.65
Earnings Yield-17.91%
FCF Yield-12.06%
Dividend Yield0.00%
Gross Margin86.75%
Oper. Margin-9.57%
Profit Margin-8.74%
Debt/Eq0.02
Current Ratio4.16
Quick Ratio4.16
Volume442.03K
Avg Volume52.54K
EPS Surprise0.68
Investment DNA
How strong this company looks for long-term investors
47
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
47/100
Why this score▼
Positive revenue growth · 44.7%Manageable debt level · 0.02Healthy liquidity · 4.16Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 1 analyst votes · 2026-09-05
100/100
Bullish
Bullish
1
Hold
0
Bearish
0
Insider Transactions
Recent executive and insider activity
Sheehy Christine Elise
Transaction: 02/11/2026
BUY
Change
+12,500
Price
Not reported
Filing
02/13/2026
Type
BUY
DeSilva Tara
Transaction: 02/11/2026
BUY
Change
+3,250
Price
Not reported
Filing
02/13/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| BSG Series CM, LLC | OTHER | 0 | Not reported | 04/24/2026 | 05/04/2026 |
| Sheehy Christine Elise | BUY | +12,500 | Not reported | 02/11/2026 | 02/13/2026 |
| DeSilva Tara | BUY | +3,250 | Not reported | 02/11/2026 | 02/13/2026 |
| Salkind Gene | BUY | +3,250 | Not reported | 02/11/2026 | 02/13/2026 |
| Yerace Daniel Alexander | BUY | +20,000 | Not reported | 02/11/2026 | 02/13/2026 |
| Cochran Christopher P. | BUY | +3,250 | Not reported | 02/11/2026 | 02/13/2026 |
| Mehalick David | BUY | +51,250 | Not reported | 02/11/2026 | 02/13/2026 |
| Calise Chris | BUY | +5,700 | $10.56 | 02/11/2026 | 02/13/2026 |
| Deschamps Philippe | BUY | +3,250 | Not reported | 02/11/2026 | 02/13/2026 |
| Cogley Brian | BUY | +10,000 | $10.56 | 02/11/2026 | 02/13/2026 |
| Deschamps Philippe | BUY | +5,700 | $10.56 | 03/04/2025 | 03/10/2025 |
| Calise Chris | BUY | +5,700 | $10.56 | 03/04/2025 | 03/06/2025 |
| Cochran Christopher P. | BUY | +5,700 | $10.56 | 03/04/2025 | 03/06/2025 |
| DeSilva Tara | BUY | +5,700 | $10.56 | 03/04/2025 | 03/06/2025 |
| Mehalick David | BUY | +28,875 | $10.56 | 03/04/2025 | 03/06/2025 |
| Salkind Gene | BUY | +5,700 | $10.56 | 03/04/2025 | 03/06/2025 |
| Sheehy Christine Elise | BUY | +1,000 | $10.56 | 03/04/2025 | 03/06/2025 |
| Yerace Daniel Alexander | BUY | +5,000 | $10.56 | 03/04/2025 | 03/06/2025 |
| Cogley Brian | BUY | +10,000 | $10.56 | 03/04/2025 | 03/06/2025 |
| Cogley Brian | SELL | 0 | Not reported | 01/10/2024 | 01/17/2024 |